Sunrest Lifescience Ltd
Incorporated in 2017, Sunrest Lifescience Ltd trades in Health care and Cosmetics products[1]
- Market Cap ₹ 18.8 Cr.
- Current Price ₹ 43.7
- High / Low ₹ 61.0 / 29.6
- Stock P/E 10.4
- Book Value ₹ 38.6
- Dividend Yield 0.00 %
- ROCE 13.6 %
- ROE 13.2 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 1.12 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has high debtors of 210 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 10.64 | 15.79 | 24.60 | 24.64 | 29.48 | 33.12 | |
| 10.49 | 15.51 | 23.49 | 21.74 | 28.57 | 30.12 | |
| Operating Profit | 0.15 | 0.28 | 1.11 | 2.90 | 0.91 | 3.00 |
| OPM % | 1.41% | 1.77% | 4.51% | 11.77% | 3.09% | 9.06% |
| 0.00 | 0.00 | 0.02 | 0.03 | 0.00 | 0.00 | |
| Interest | 0.00 | 0.01 | 0.02 | 0.06 | 0.22 | 0.30 |
| Depreciation | 0.02 | 0.04 | 0.06 | 0.13 | 0.10 | 0.09 |
| Profit before tax | 0.13 | 0.23 | 1.05 | 2.74 | 0.59 | 2.61 |
| Tax % | 76.92% | 21.74% | 25.71% | 25.55% | 61.02% | 23.37% |
| 0.04 | 0.17 | 0.78 | 2.04 | 0.23 | 2.00 | |
| EPS in Rs | 40.00 | 170.00 | 780.00 | 6.80 | 0.54 | 4.66 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 26% |
| 3 Years: | 10% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 119% |
| 3 Years: | 38% |
| TTM: | 770% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -23% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 19% |
| 3 Years: | 16% |
| Last Year: | 13% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 0.01 | 3.00 | 4.29 | 4.29 | 4.29 |
| Reserves | 0.12 | 0.28 | 1.06 | 0.11 | 9.89 | 11.89 | 12.28 |
| 2.27 | 2.31 | 3.24 | 2.14 | 6.16 | 6.17 | 7.91 | |
| 3.85 | 6.88 | 8.71 | 11.47 | 4.82 | 12.81 | 10.69 | |
| Total Liabilities | 6.25 | 9.48 | 13.02 | 16.72 | 25.16 | 35.16 | 35.17 |
| 0.03 | 0.15 | 0.47 | 0.35 | 0.26 | 1.32 | 1.27 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 | 5.52 | 5.52 |
| 6.22 | 9.33 | 12.55 | 16.35 | 24.88 | 28.32 | 28.38 | |
| Total Assets | 6.25 | 9.48 | 13.02 | 16.72 | 25.16 | 35.16 | 35.17 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| -0.90 | 0.15 | -0.44 | 1.15 | -14.80 | 1.43 | |
| -0.01 | -0.16 | -0.36 | -0.03 | -0.01 | -1.14 | |
| 1.11 | 0.04 | 0.90 | -1.15 | 14.64 | -0.30 | |
| Net Cash Flow | 0.20 | 0.03 | 0.11 | -0.03 | -0.16 | -0.01 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 184.22 | 171.06 | 138.73 | 160.87 | 185.72 | 209.50 |
| Inventory Days | 23.71 | 48.88 | 48.05 | 96.71 | 92.25 | 124.85 |
| Days Payable | 174.84 | 206.14 | 165.68 | 211.59 | 69.42 | 209.62 |
| Cash Conversion Cycle | 33.08 | 13.80 | 21.10 | 46.00 | 208.55 | 124.73 |
| Working Capital Days | 69.64 | 47.16 | 47.33 | 62.96 | 210.85 | 148.12 |
| ROCE % | 9.60% | 30.39% | 58.58% | 6.33% | 13.63% |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Trade Receivable Turnover Ratio Times |
|
||
| Medical Representatives (MR) Reimbursement Expense INR Lakhs |
|||
| Number of Employees Number |
|||
| Number of Subsidiaries Number |
|||
Documents
Announcements
-
Outcome of Board Meeting
13 February 2026 - Board approved rights issue to raise up to Rs15.10 crore; DLOF approved; NSE approval pending.
-
Trading Window
10 February 2026 - Trading window closed Feb 10 until 48 hours after Feb 13 board meeting for proposed equity/preferential fundraise.
-
Resignation
16 January 2026 - Resignation of CS Neelam Gattani effective 13 Jan 2026; Nabil Ansari appointed CS & Compliance Officer effective 16 Jan 2026.
-
Change in Company Secretary/Compliance Officer
16 January 2026 - CS Neelam Gattani resigned effective 13 Jan 2026; CS Nabil Ansari appointed effective 16 Jan 2026.
-
Appointment
16 January 2026 - Resignation of CS Neelam Gattani effective 13 Jan 2026; Nabil Ansari appointed CS effective 16 Jan 2026.
Business Overview:[1][2]
SLSL is in the business of trading of Pharmaceutical Product on wholesale and retail basis. It provides OTC brands in healthcare & personal care viz. Capsules, Tablets, Syrup, Ointment, Gel, mouthwash, Solution, Suspension, Dry Powders, and Toothpaste